drugset / Trial / NCT05169684
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after novel antiandrogen therapy and have not received chemotherapy for mCRPC.
Timeline
- Start
- 2022-02-14
- Primary completion
- 2023-12-06
- Completion
- 2023-12-06
Outcome
Outcome not reported
Stopped (Business): “Business objectives have changed”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986218 | Monoclonal antibody | — | — |
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |